Sarepta Therapeutics Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: July 19th, 2021
Here are a few of the most interesting Sarepta Therapeutics statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Sarepta Therapeutics Facts
- Website: Official Website
- Year Founded: 1980
- Headquarters: Cambridge, MA
- Current Chief Executive: Douglas Ingram
What is Sarepta Therapeutics?
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. (source)
Sarepta Therapeutics Employee Count
Number of Sarepta Therapeutics employees:
Last updated 1/1/20
Sarepta Therapeutics Revenue Totals
Sarepta Therapeutics annual revenue:
- 2019: $380 million
- 2018: $301 million
- 2017: $154 million
- 2016: $5 million
- 2015: $1 million
Sarepta Therapeutics annual net income:
- 2019: $715 million net loss
- 2018: $361 million net loss
- 2017: $50 million net loss
- 2016: $267 million net loss
- 2015: $220 million net loss
Please note that some of these numbers are easier to find than others. A few of these Sarepta Therapeutics stats come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.